Recent News

• 09.09.2025 - H.C. Wainwright Global Investment Conference
• 08.28.2025 - Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
• 06.25.2025 - Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
• 05.14.2025 - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
• 05.14.2025 - Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Recent Filings

• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.12.2025 - 8-K Current report
• 08.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - EX-99.1 EX-99.1
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 8-K Current report
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.09.2025 - 4 Statement of changes in beneficial ownership of securities